“Overall,” Dr. Hazlewood concludes, “the impact on RA management will be small, as biologic therapy is rarely if ever used as first-line treatment.”
UCB Pharma sponsored the study. A number of authors including Dr. Emery have relationships with UCB Pharma, and several are employed by the company.